KR20130083376A - 비강내 전달을 위한 방법 및 조성물 - Google Patents

비강내 전달을 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20130083376A
KR20130083376A KR1020127025573A KR20127025573A KR20130083376A KR 20130083376 A KR20130083376 A KR 20130083376A KR 1020127025573 A KR1020127025573 A KR 1020127025573A KR 20127025573 A KR20127025573 A KR 20127025573A KR 20130083376 A KR20130083376 A KR 20130083376A
Authority
KR
South Korea
Prior art keywords
virus
antigens
vaccine
powder formulation
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127025573A
Other languages
English (en)
Korean (ko)
Inventor
료이치 나가타
?지 하루타
Original Assignee
신 니뽄 바이오메디칼 라보라토리즈, 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. filed Critical 신 니뽄 바이오메디칼 라보라토리즈, 엘티디.
Publication of KR20130083376A publication Critical patent/KR20130083376A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M3/00—Automatic or semi-automatic exchanges
    • H04M3/42—Systems providing special services or facilities to subscribers
    • H04M3/50—Centralised arrangements for answering calls; Centralised arrangements for recording messages for absent or busy subscribers ; Centralised arrangements for recording messages
    • H04M3/51—Centralised call answering arrangements requiring operator intervention, e.g. call or contact centers for telemarketing
    • H04M3/5116—Centralised call answering arrangements requiring operator intervention, e.g. call or contact centers for telemarketing for emergency applications
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/90—Services for handling of emergency or hazardous situations, e.g. earthquake and tsunami warning systems [ETWS]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W76/00—Connection management
    • H04W76/50—Connection management for emergency connections
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W76/00—Connection management
    • H04W76/10—Connection setup
    • H04W76/15—Setup of multiple wireless link connections
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/18—Processing of user or subscriber data, e.g. subscribed services, user preferences or user profiles; Transfer of user or subscriber data
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Signal Processing (AREA)
  • Business, Economics & Management (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Emergency Management (AREA)
  • Environmental & Geological Engineering (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marketing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020127025573A 2010-04-15 2011-04-15 비강내 전달을 위한 방법 및 조성물 Ceased KR20130083376A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32454210P 2010-04-15 2010-04-15
US61/324,542 2010-04-15
PCT/JP2011/002225 WO2011129120A1 (en) 2010-04-15 2011-04-15 Methods and compositions for intranasal delivery

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020127030060A Division KR101960102B1 (ko) 2010-04-15 2011-04-15 비강내 전달을 위한 방법 및 조성물
KR1020197006392A Division KR102136036B1 (ko) 2010-04-15 2011-04-15 비강내 전달을 위한 방법 및 조성물

Publications (1)

Publication Number Publication Date
KR20130083376A true KR20130083376A (ko) 2013-07-22

Family

ID=44798502

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020127025573A Ceased KR20130083376A (ko) 2010-04-15 2011-04-15 비강내 전달을 위한 방법 및 조성물
KR1020197006392A Expired - Fee Related KR102136036B1 (ko) 2010-04-15 2011-04-15 비강내 전달을 위한 방법 및 조성물
KR1020127030060A Active KR101960102B1 (ko) 2010-04-15 2011-04-15 비강내 전달을 위한 방법 및 조성물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197006392A Expired - Fee Related KR102136036B1 (ko) 2010-04-15 2011-04-15 비강내 전달을 위한 방법 및 조성물
KR1020127030060A Active KR101960102B1 (ko) 2010-04-15 2011-04-15 비강내 전달을 위한 방법 및 조성물

Country Status (12)

Country Link
US (2) US9687536B2 (https=)
EP (2) EP2689785B1 (https=)
JP (5) JP5771626B2 (https=)
KR (3) KR20130083376A (https=)
CN (3) CN103126996A (https=)
BR (1) BR112012026116A2 (https=)
CA (2) CA2796593C (https=)
CU (1) CU20120148A7 (https=)
ES (1) ES2874817T3 (https=)
RU (1) RU2012144612A (https=)
SG (1) SG184304A1 (https=)
WO (1) WO2011129120A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103126996A (zh) 2010-04-15 2013-06-05 株式会社新日本科学 用于鼻内递送的方法和组合物
BR112014014594B1 (pt) 2011-12-16 2021-02-17 Indosys Limited dispositivo de liberação de medicamento seco em pó
TWI690322B (zh) * 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
CN104208029B (zh) * 2013-05-30 2017-06-06 上海医药工业研究院 一种鼻用疫苗组合物粉体制剂及其制备方法
EP3041504B1 (en) 2013-09-03 2021-08-25 Georgia Tech Research Corporation Thermally stable vaccine formulations and microneedles
DK3049059T3 (da) 2013-09-24 2022-01-31 Satsuma Pharmaceuticals Inc Intranasal dhe formulering til behandlingen af hovedpine
IL310015B2 (en) * 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
EP3127550A1 (en) * 2015-08-07 2017-02-08 HSC Development GmbH Stabilizing composition for dry formulation of virus
WO2017047089A1 (en) * 2015-09-16 2017-03-23 Shin Nippon Biomedical Laboratories, Ltd. Vaccine compositions
GB201610628D0 (en) * 2016-06-17 2016-08-03 Mihranyan Albert New compositions
US20190275136A1 (en) * 2016-09-19 2019-09-12 Vaxess Technologies, Inc. Vaccine formulations with increased stability
US11022115B2 (en) 2017-06-02 2021-06-01 Purdue Research Foundation Controlled variable delivery external gear machine
JPWO2019021957A1 (ja) * 2017-07-25 2020-07-09 第一三共株式会社 点鼻用乾燥粉末医薬組成物
GB201713899D0 (en) 2017-08-30 2017-10-11 Indosys Ltd Multi-dose medicament delivery device
WO2019118393A1 (en) 2017-12-11 2019-06-20 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
AU2019336940B2 (en) * 2018-09-06 2025-09-11 Bavarian Nordic A/S Storage improved poxvirus compositions
CN120284965A (zh) 2018-12-11 2025-07-11 小蜜橘制药公司 用于治疗或预防头痛的组合物、装置和方法
BR112021016059A2 (pt) * 2019-02-15 2021-10-13 Serum Institute Of India Pvt Ltd. Composição de vacina de vírus de influenza atenuada viva e processo para a preparação da mesma
EP3698773A1 (en) 2019-02-21 2020-08-26 Università degli Studi di Parma Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination
US11621604B2 (en) 2020-02-16 2023-04-04 Purdue Research Foundation Integrated electro-hydraulic machine
WO2021194038A1 (ko) * 2020-03-24 2021-09-30 안병철 어린 포유동물의 점막관련 전염성 질병을 예방 또는 치료하기 위한 혈청 조성물의 제조방법, 상기 방법에 의해 제조된 혈청 조성물 및 이의 용도
CN113583970B (zh) * 2021-07-29 2023-05-12 吉林大学 一种用于预防或抗冠状病毒传播、致病的药物及其制备方法
CN119866231A (zh) 2022-09-01 2025-04-22 锡拉坎岛有限公司 干粉药物递送装置
JP2025540325A (ja) * 2022-12-07 2025-12-11 ズー，ダオチョン 融合タンパク質の製剤および使用
WO2024228212A1 (en) * 2023-05-01 2024-11-07 Biovet Private Limited Bio-lumpivaxin formulations and method of preparation thereof
AU2024282997A1 (en) * 2023-05-31 2026-01-22 Shin Nippon Biomedical Laboratories, Ltd. Compositions for enhanced mucosal penetration
GB202403611D0 (en) 2024-03-13 2024-04-24 Therakind Ltd Improved multi-dose medicament delivery device
CN118924744A (zh) * 2024-07-29 2024-11-12 复旦大学 小分子抑制剂ha15在抗乙型肝炎病毒中的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009819A1 (en) * 1992-11-03 1994-05-11 Secretech, Inc. Microcrystalline cellulose as an immune adjuvant
US20030092145A1 (en) 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
CN1193745C (zh) * 2001-02-27 2005-03-23 国家医药管理局上海医药工业研究院 一种鼻用鲑降钙素粉末吸入剂及制备方法
AU2002346424A1 (en) 2001-11-19 2003-06-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
EP1701738B1 (en) * 2003-12-17 2015-03-11 Wyeth LLC Method for producing storage stable RSV compositions
US20060292173A1 (en) * 2004-12-13 2006-12-28 Macadam Donald H Multibacterial vaccines and uses thereof
EP1954308B1 (en) 2005-09-16 2011-09-07 Merial Ltd. Stabilizers for freeze-dried vaccines
AU2006299310A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
BRPI0616879A2 (pt) * 2005-10-04 2011-07-05 Alk Abello As formulação de vacina sólida
BRPI0707733B1 (pt) 2006-02-13 2019-12-31 Ibio, Inc. antígeno isolado, composição de vacina, uso da referida composição e método para produção de uma proteína de antígeno
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
ITMI20061117A1 (it) * 2006-06-09 2007-12-10 Michele Bonanomi Una composizione farmaceutica per la somministrazione sublinguale di vaccini metodo per la sua preparazione e sui usi
US20080226729A1 (en) 2006-09-08 2008-09-18 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
EP2066354B1 (en) * 2006-09-29 2013-04-17 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
CA2681567C (en) * 2007-03-22 2016-07-19 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
WO2009006299A2 (en) 2007-06-29 2009-01-08 Dr. Reddy's Laboratories Ltd. Multi-particulate systems
CN101959527B (zh) * 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
CN101601860A (zh) * 2008-06-13 2009-12-16 中国科学院过程工程研究所 疫苗
US20110150926A1 (en) 2008-08-01 2011-06-23 Mohammed Alsharifi Influenza vaccines
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
JP5491119B2 (ja) * 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
AU2012244077B2 (en) 2010-04-15 2015-06-18 Shin Nippon Biomedical Laboratories, Ltd. Methods and compositions for intranasal delivery
CN103126996A (zh) * 2010-04-15 2013-06-05 株式会社新日本科学 用于鼻内递送的方法和组合物

Also Published As

Publication number Publication date
US20130129781A1 (en) 2013-05-23
CN102933230A (zh) 2013-02-13
JP2016006119A (ja) 2016-01-14
CA2796593C (en) 2020-12-15
JP6827488B2 (ja) 2021-02-10
CA2993242A1 (en) 2011-10-20
US10463723B2 (en) 2019-11-05
CN102933230B (zh) 2016-03-02
JP2013126989A (ja) 2013-06-27
CN103126996A (zh) 2013-06-05
RU2012144612A (ru) 2014-05-20
KR101960102B1 (ko) 2019-03-19
CA2993242C (en) 2020-12-15
BR112012026116A2 (pt) 2016-06-28
KR20130064741A (ko) 2013-06-18
EP2689785A1 (en) 2014-01-29
CA2796593A1 (en) 2011-10-20
CN107260689A (zh) 2017-10-20
US9687536B2 (en) 2017-06-27
ES2874817T3 (es) 2021-11-05
JP2017186377A (ja) 2017-10-12
JP2013523602A (ja) 2013-06-17
KR102136036B1 (ko) 2020-07-20
JP2019104751A (ja) 2019-06-27
JP5771626B2 (ja) 2015-09-02
CU20120148A7 (es) 2013-01-30
EP2558120A1 (en) 2013-02-20
EP2558120A4 (en) 2013-08-28
WO2011129120A1 (en) 2011-10-20
KR20190028555A (ko) 2019-03-18
SG184304A1 (en) 2012-11-29
US20130273120A1 (en) 2013-10-17
EP2689785B1 (en) 2021-05-19

Similar Documents

Publication Publication Date Title
KR102136036B1 (ko) 비강내 전달을 위한 방법 및 조성물
JP7082703B2 (ja) ワクチン組成物
Tian et al. Intradermal administration of influenza vaccine with trehalose and pullulan-based dissolving microneedle arrays
JP2016535065A (ja) 熱安定性ワクチン製剤及びマイクロニードル
CA2680193C (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
CN106456585B (zh) 疫苗组合物
US10980871B2 (en) Vaccine compositions
US20220325250A1 (en) Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
AU2012244074B2 (en) Methods and compositions for intranasal delivery
Beukema Intradermal administration of influenza accine ith trehalose and pullulan-based dissol ing microneedle arra s

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120928

Patent event code: PA01051R01D

Comment text: International Patent Application

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20121116

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160414

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170828

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180330

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20181128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180330

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20170828

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20181128

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180702

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20171030

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20160414

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20121116

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190129

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20181228

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20181128

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180702

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180330

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20171030

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20170828

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160414

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20121116

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190304